Leverkusen - Bayer AG on Tuesday successfully placed new senior bonds with a total volume of 3 billion euros under its Debt Issuance Program.

The issuance comprises three tranches and was about four times covered. Bayer intends to list the bonds on the Regulated Market of the Luxembourg Stock Exchange. The proceeds are to be used for general corporate purposes.

The three tranches with volumes of 750 million euros, 750 million euros and 1.5 billion euros have maturities of 3.25 years, 6.25 years and 10 years, respectively. The coupons of the notes are 4.000 percent p.a., 4.250 percent p.a. and 4.625 percent p.a., respectively. The notes have been issued in denominations of 1,000 euros.

The notes are expected to be rated Baa2, BBB and BBB+ by Moody's, Standard & Poor's and Fitch, respectively.

'The high level of oversubscription of our new bonds reflects investors' confidence in Bayer's development,' said Bayer CFO Wolfgang Nickl.

BofA Securities, Citi and Deutsche Bank led the transaction as Joint Active Bookrunners.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contact:

Tino Andresen

Email: tino.andresen@bayer.com

Tel: +49 214 30-66048

(C) 2023 Electronic News Publishing, source ENP Newswire